1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-(aminomethyl)-1$l^{5}-pyridin-1-ylium

• ChemBase编号: 3444
• 分子式: C21H29N7O13P2
• 平均质量: 649.441582
• 单一同位素质量: 649.12985728
• SMILES: NCc1ccc[n+](c1)[C@@H]1O[C@@H](COP(=O)([O-])O[P@](=O)(O)OC[C@@H]2O[C@H]([C@H](O)[C@H]2O)n2cnc3c2ncnc3N)[C@H](O)[C@H]1O
• Canonical SMILES: NCc1ccc[n+](c1)[C@@H]1O[C@H]([C@@H]([C@H]1O)O)COP(=O)(O[P@@](=O)(OC[C@@H]1O[C@H]([C@@H]([C@H]1O)O)n1cnc2c1ncnc2N)O)[O-]
• InChI: InChI=1S/C21H29N7O13P2/c22-4-10-2-1-3-27(5-10)20-16(31)14(29)11(39-20)6-37-42(33,34)41-43(35,36)38-7-12-15(30)17(32)21(40-12)28-9-26-13-18(23)24-8-25-19(13)28/h1-3,5,8-9,11-12,14-17,20-21,29-32H,4,6-7,22H2,(H3-,23,24,25,33,34,35,36)/t11-,12-,14-,15-,16+,17+,20+,21+/m0/s1
• InChIKey: HMCRLFVYYFBZEZ-OQSIOIOUSA-N

名称和登记号

名称

• IUPAC标准名: 1-[(2R,3R,4R,5S)-5-({[(S)-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-3-(aminomethyl)-1$l^{5}-pyridin-1-ylium
• IUPAC传统名: 3-(aminomethyl)-1-[(2R,3R,4R,5S)-5-({[(S)-([(2S,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy(hydroxy)phosphoryl phosphonato)]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium
• 别名: 3-Aminomethyl-Pyridinium-Adenine-Dinucleotide

登记号

• PubChem SID: 46506667; 160966883
• PubChem CID: 46936792

理论计算性质

JChem

• 质子供体: 7
• LogD (pH = 5.5): -13.584812
• LogD (pH = 7.4): -12.249929
• Log P: -13.5047035
• 摩尔折射率: 140.2702 cm^3
• 极化性: 56.54999 Å^3
• 极化表面积: 304.02 Å^2
• 可自由旋转的化学键: 11
• 里宾斯基五规则: false
• Acid pKa: 1.7855344
• 质子受体: 15

ALOGPS 2.1

• Log P: -1.7
• LOG S: -2.5
• 溶解度: 2.21e+00 g/l

详细说明

DrugBank - DB03797

Drug information: experimental